Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Kidney Disease Investigation(Electronic Edition) ›› 2016, Vol. 05 ›› Issue (06): 265-268. doi: 10.3877/cma.j.issn.2095-3216.2016.06.006

Special Issue:

• Original Article • Previous Articles     Next Articles

Effect of Huangkui capsule combined with Jianpiyishen decoction on CKD patients with Pishengyangxu syndrome

Chunhua Cao1, Na Wang1, Yaping Yu1, Xudong Cong2, Teng Ma1, Dexi Peng1, Ying Zhou1, Xueqin Gu1, Chengye Yuan1,()   

  1. 1. Department of Nephrology, Taizhou Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Taizhou 225300, Jiangsu Province, China
    2. SZYY Group Pharmaceutical Ltd, Taizhou 225300, Jiangsu Province, China
  • Received:2016-11-18 Online:2016-12-28 Published:2016-12-28
  • Contact: Chengye Yuan
  • About author:
    Corresponding author: Yuan Chengye, Email:

Abstract:

Objective

To observe the clinical effect of Huangkui capsule combined with Jianpiyishen decoction on chronic kidney disease (CKD stage 3-4) patients with Pishengyangxu syndrome.

Methods

58 patients were randomly divided into treatment group (28 cases) and control group (30 cases). Both groups received the basic treatment of western medicine and the Jianpiyishen recipe (1 dose/day, decoction 100 ml/time, twice a day for 3 months). The treatment group was added with oral Huangkui capsule, 5 capsules/time, thrice a day for 3 months. Before treatment, and 3 months after the treatment, the following were detected: Hb, Alb, TC, TG, BUN, Cr, UA, eGFR, C-reactive protein (CRP), beta 2 microglobulin (β2-MG), serum superoxide dismutase (SOD), malondialdehyde (MDA), endothelin (ET), and nitric oxide (NO).

Results

Compared with the control group, the treatment group showed significantly higher levels of Hb, Alb, NO, SOD, and eGFR (P<0.05) 3 months after the treatment, but showed significantly lower levels of TC, TG, BUN, Cr, UA, CRP, MDA, β2-MG, ET, and DBP (P<0.05), with all the differences being statistically significant. Both the primary and secondary manifestations of TCM Pishengyangxu syndrome disappeared, and the secondary sthenia syndrome manifestations were reduced.

Conclusion

The effect of Huangkui capsule combined with Jianpiyishen formula on CKD (stage 3-4) patients with Pishengyangxu syndrome was better than that of Jianpiyishen recipe alone.

Key words: Huangkui capsule, Jianpiyishen, Pishengyangxu

京ICP 备07035254号-35
Copyright © Chinese Journal of Kidney Disease Investigation(Electronic Edition), All Rights Reserved.
Tel: 010-66937011 E-mail: zhsbyj@126.com
Powered by Beijing Magtech Co. Ltd